Aarti Pharmalabs Declares Interim Dividend of ₹1.5/Share, Approves Q3 FY26 Results
Aarti Pharmalabs declared an interim dividend of ₹1.50 per share for FY25-26. The Board approved unaudited financial results for Q3 and nine months ended Dec 31, 2025. Standalone revenue from operations for Q3 was ₹255.28 crore and consolidated was ₹378.74 crore. The record date for the dividend is Feb 16, 2026.
The declaration of an interim dividend is a direct financial benefit to shareholders. The financial results provide key performance indicators for the company.
The declaration of an interim dividend and approval of financial results are generally positive indicators for a company.
Aarti Pharmalabs Limited announced the outcome of its Board Meeting held on February 09, 2026. The Board of Directors approved the unaudited financial results for the quarter and nine months ended December 31, 2025, both on a standalone and consolidated basis, following the recommendation of the Audit Committee. Concurrently, the Board declared an interim dividend of ₹1.50 per equity share (30%) for the Financial Year 2025-26. The record date for the payment of this interim dividend has been fixed as February 16, 2026.
The financial results for the quarter and nine months ended December 31, 2025, show standalone revenue from operations at ₹25528.07 lakhs and consolidated revenue from operations at ₹37873.81 lakhs for the quarter. For the nine months ended December 31, 2025, standalone revenue from operations was ₹72878.00 lakhs, and consolidated revenue from operations was ₹105197.59 lakhs.
The company also reported an exceptional item of ₹279.09 lakhs related to the impact of new labor codes. A note highlights that revenue of ₹4,935 lakhs for goods shipped in Q3 FY26 but in-transit is included as stock in transit, with the goods reaching their destination in Q4.
What to do with a filing like this
Aarti Pharmalabs Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Aarti Pharmalabs Limited. Read the original for the full detail.